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OBJECTIVEdTo compare two validated closed-loop (CL) algorithms versus patient self-
control with CSII in terms of glycemic control.
RESEARCH DESIGN AND METHODSdThis study was a multicenter, randomized,
three-way crossover, open-label trial in 48patientswith type 1diabetesmellitus for at least 6months,
treatedwith continuous subcutaneous insulin infusion. Blood glucosewas controlled for 23 h by the
algorithm of theUniversities of Pavia and Padovawith a Safety SupervisionModule developed at the
Universities of Virginia andCalifornia at Santa Barbara (international artiﬁcial pancreas [iAP]), by the
algorithm of University of Cambridge (CAM), or by patients themselves in open loop (OL) during
three hospital admissions including meals and exercise. The main analysis was on an intention-to-
treat basis. Main outcome measures included time spent in target (glucose levels between 3.9 and
8.0 mmol/L or between 3.9 and 10.0 mmol/L after meals).
RESULTSdTime spent in the target range was similar in CL and OL: 62.6% for OL, 59.2% for
iAP, and 58.3% for CAM.While mean glucose level was signiﬁcantly lower in OL (7.19, 8.15, and 8.26
mmol/L, respectively) (overall P = 0.001), percentage of time spent in hypoglycemia (,3.9mmol/L) was
almost threefold reduced during CL (6.4%, 2.1%, and 2.0%) (overall P = 0.001) with less time #2.8
mmol/L (overall P = 0.038). There were no signiﬁcant differences in outcomes between algorithms.
CONCLUSIONSdBoth CAM and iAP algorithms provide safe glycemic control.
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The burden of managing type 1 di-abetes mellitus (T1DM) is consider-able for the patient (1). Automating
glucose measurements and insulin ad-
ministration may ease diabetes manage-
ment. This is known as a “closed-loop
system” or “artiﬁcial pancreas” (AP). A
computer algorithm determines insulin
infusion rates from continuously mea-
sured glucose levels, aiming to keep glu-
cose levels within target range. AP
systems have a long development history
(2). One of the earliest systems was
the Biostator device (Miles Laboratories,
Elkhart, IN), which entered the market in
1977 (3). The Biostator was a bedside de-
vice that required intravenous access to
determine blood glucose and infuse in-
sulin or glucose. The necessity of intrave-
nous access limited usability of the device
to in-hospital settings. Outpatient use be-
came conceivable with the advent of con-
tinuous glucose monitoring (CGM)
systems, which measure glucose in inter-
stitial ﬂuid via placement of a sensor in the
subcutaneous fat. Although subcutane-
ous CGMcombinedwith continuous sub-
cutaneous insulin infusion (CSII) allowed
for closed-loop (CL) experiments, CGMac-
curacy needs to be improved upon and is
considered to be one of the limiting factors
in development of AP systems (4,5). CL
algorithms should take into account the
uncertainty surrounding CGM reported
glucose values, as well as the delay of in-
sulin action after its administration. Many
current algorithms used to develop an AP
are based on model predictive control
(MPC) (6,7), while others are based
on the proportional-integral-derivative
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approach (8–11), which may also use in-
sulin feedback (12). MPC can be used to
take into account limited CGM accuracy,
delays in insulin absorption, and glucose
peaks brought about by meals (4). This
work aims to compare twoCL algorithms:
one from the University of Cambridge
(CAM) and the other from collaboration
between the Universities of Pavia, Padova
(13); University of Virginia; and Univer-
sity of California at Santa Barbara (inter-
national AP [iAP]) (14) against patient
self-management (open loop [OL]). Both
algorithms use MPC to control blood glu-
cose levels and have shown that their use
leads to diminished occurrence of hypo-
glycemia at night when used for CL con-
trol in small-scale clinical research center
(CRC) trials (15,16). The CAM algorithm is
initialized using the subject’s weight, total
daily insulin, and the basal 24-h pump
proﬁle, while the iAP algorithm uses the
subject’s weight and basal 24-h pump
proﬁle. The iAP but not CAM algorithm
also uses information about correction
factors, insulin-to-carbohydrate ratios,
and pump setting during exercise. Both
algorithms use mealtime announcement
to apply prandial insulin boluses, which
has been shown to lead to improved post-
prandial glucose excursions (17); how-
ever, while the CAM algorithm uses this
information to administrate the meal bo-
lus computed with the conventional ther-
apy, the iAP meal bolus is automatically
computed by the MPC control algorithm
including in the cost function the con-
ventional therapy as references. The
CAM algorithm uses a two-compartment
model of glucose kinetics and a three-
compartment model of insulin action
solved analytically for computational speed
and robustness. The model is adapted at
each control cycle to a particular subject
by modifying two model parameters rep-
resenting unexplained glucose ﬂux to ac-
commodate the prediction error and
meal carbohydrate bioavailability. In ad-
dition, several versions of the model are
tested to assess the likelihood of slow/fast
insulin absorption and slow/fast meal ab-
sorption. The versions are combined in
a probabilistic fashion taking into ac-
count prediction accuracy of each model
version. The iAP MPC algorithm uses
the mean linearized model of the in
silico population of the U.S. Food and
Drug Administration–approved Virginia/
Padova simulator for all the patients. Both
algorithms are only aware of the CGM
data monitored during the trial and do
not take into account safety blood glucose
values measured for safety reasons during
trials. Recent results on a near full-day
study showed that the iAP algorithm re-
ducedmean glucose concentrationwithout
increasing hypoglycemia (18). This study
aims to assess safety of these systems on a
broader scale, i.e., in a large series of 48
patients investigated in several clinical re-
search sites, including centers naïve to such
trials, in order to increase external validity
of the reported results. Secondly, we
wanted to extend duration of experiments
beyond nighttime to encompass a near full
day (23 h). By doing this, we were able to
test the algorithms’ ability to cope with
meals and exercise, which are important
challenges for CL control (4,11,18,19).
RESEARCH DESIGN AND
METHODSdForty-eight patients with
T1DM were included in this three-way
randomized crossover intervention study
in six clinical centers (Academic Medical
Center, Amsterdam, the Netherlands;
Centre Hospitalier Regional Universitaire,
Montpellier, France; Medical University,
Graz, Austria; Proﬁl Institute for Meta-
bolic Research GmbH, Neuss, Germany;
University of Cambridge, Cambridge,
U.K.; and University of Padova, Padova,
Italy). The study was powered to detect a
5% difference in time in target between
any of the two algorithms (primary out-
come) with 90% power and an a of 0.05
(N = 44). Allowing for dropout, we in-
cluded eight patients per center (n = 48).
The trial was conducted in accordance
with the ethics principles set forth in the
Declaration of Helsinki and was approved
by the medical ethics committees of par-
ticipating centers.
Main inclusion criteria included age
$18 years and T1DM treated with CSII
with a rapid-acting insulin analog for at
least 3 months. Main exclusion criteria in-
cluded pregnancy and use of medications
that signiﬁcantly impact glucose metabo-
lism (Supplementary Table 1). Patients
visited the CRC for an inclusion visit
and provided informed consent. The re-
mainder of the inclusion visit included
CGM training and determination or esti-
mation of VO2max.
The main intervention comprised
three 24-h admissions (duration of in-
tervention 23 h) to the CRC during which
patients underwent the study interven-
tions in random order (CL with CAM or
iAP and OL). Admissions were at least 1
week apart to prevent carry-over effects.
Between 24 and 48 h before admission, a
nonblinded Dexcom Seven Plus CGM
sensor (Dexcom, San Diego, CA) was
placed and calibrated using ﬁnger-stick
glucose values. During each study visit,
CGM was calibrated with plasma glucose
measurements performed either with
a YSI (YSI, Yellow Springs, OH) (Graz,
Neuss, and Padova) or with a blood
glucose meter (Roche Diagnostics, Mann-
heim, Germany) (Amsterdam, Cambridge,
and Montpellier). Calibration was per-
formed four times per 24 h: at 1875 h
(before dinner), 2300 h (before bed-
time), 0700 h (before breakfast), and
1450 h (before exercise). At the beginning
of each admission, an Omnipod Insulin
Patch-Pump (Insulet, Bedford, MA) ﬁlled
with insulin aspart (Novo Nordisk,
Bagsvaerd, Denmark) was placed on the
abdomen. The CL algorithms ran on a
personal computer loadedwithWindows
XP Professional (Microsoft, Redmond,
WA), and code was executed using
MatLab 2009b (MathWorks, Natick,
MA) in case of iAP and as a separate execut-
able in case of CAM. The CL algorithm was
fed with CGM data either automatically
(Amsterdam, Montpellier, and Padova)
or by manual transfer of glucose data
(Cambridge, Graz, and Neuss), depend-
ing on regulatory requirements and avail-
ability of devices. The algorithms were
unaware of plasma glucose values. The
CL algorithms calculated the appropriate
insulin doses, which were then automat-
ically or manually transferred to the patch
pump. The control cycle was 5 min for
iAP and 15 min for CAM in automated
centers and 15min for both algorithms in
manual centers.
In both automated and manual cen-
ters, the attending physician could over-
ride actions initiated or suggested by the
CL algorithm at any time.
Admission days
Patients arrived at theCRCat 1800 h (Fig. 1).
A meal of 80 g carbohydrates was given at
1900 h for dinner, followed by sleep from
2300 h through 0700h the next day. A 50-g
carbohydrate breakfast was given at
0800 h, followed by a 60-g carbohydrate
lunch at noon. Exercise, consisting of two
bouts of 15-min exercise at 50% VO2max,
was started at 1500 h, and the study ended
at 1800 h. Time and carbohydrate contents
of meals were announced to the system
15 min before eating. In case of the iAP
algorithm, the mealtime insulin bolus was
then calculated by the algorithm. In case of
theCAMalgorithm, the algorithmadviseda
bolus of 80% of the patient’s usually calcu-
latedmealtime bolus. In case ofOL control,
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patients treated themselves as usual with
the advice to administer mealtime boluses
15min before commencement of the meal,
as this has been shown to signiﬁcantly re-
duce postprandial glucose excursion (20).
Size of mealtime boluses was determined
by patients themselves based on carbohy-
drate contents of the meals, which was an-
nounced to them. During OL visits,
subjects were given the option of reducing
usual basal rates 1–2 h before exercise. Pa-
tients could also choose to eat a snack be-
fore exercise, while all patients were given a
snack consisting of 20 g carbohydrates if
the reference plasma glucose was ,7.8
mmol/L 30min before exercise. This snack
was announced to the iAP algorithm but
not to the CAM algorithm. In case of hypo-
glycemia measured by YSI, patients were
treated with a 15-g carbohydrate snack;
such recue carbohydrates were announced
to both algorithms. Rescue carbohydrates
were given on the basis of YSI values only at
#3.3 mmol/L in patients experiencing
symptoms of hypoglycemia and at #2.8
mmol/L in patients not experiencing symp-
toms. No additional carbohydrates were
provided to the patient other than those
mentioned before. Throughout the ad-
mission, blood was sampled for measure-
ment of plasma glucose and insulin levels
every 30 min. Blood sampling frequency
increased to every 15 min after meals and
exercise and decreased to once an hour
at night. Blood was sampled for plasma
glucose measurement using the YSI
2300STATplus analyzer (YSI).Heparinized
plasma was frozen for central determina-
tion of insulin aspart concentrations using
an insulin chemiluminescence assay (Invi-
tron, Monmouth, U.K.) (S. Luzio, The In-
stitute of Life Sciences, Swansea University,
Swansea, U.K.).
Data acquisition
An electronic clinical data-management
system was used (OpenClinica; Open-
Clinica, Waltham, MA). The CL software
also kept records of all CGM glucose data,
YSI glucose data, administered insulin
data, and information concerning meals
and exercise. All these ﬁles where checked
and locked in a central database before
data analysis.
Data analysis and outcomes
All outcome measures were predeﬁned
in a statistical analysis plan. The primary
outcome was time spent in the target
range, deﬁned as plasma glucose values
between 3.9 and 8.0 mmol/L in the basal
or late postprandial state and plasma
glucose values between 3.9 and 10.0
mmol/L in the early postprandial phase
(up to 3 h after the meals). Other out-
comes are listed in Table 1. In the case of
administration of rescue carbohydrates,
an analysis was performed on the number
of times a rescue amount was adminis-
tered. Amounts administered within a
short time of each other were not aggre-
gated into a single event. An intention-to-
treat analysis (ITT) and a per-protocol
analysis (PP) were done. The aim of the
IIT analysis was to describe overall per-
formance of the system, accepting any
failure or poor performance of any system
component (e.g., insulin pump, sensor,
algorithms, or operator failure). The aim
of the PP analysis was to describe perfor-
mance of the CL algorithms at times that
all other parts of the system were func-
tioning adequately. For the PP analysis,
time frames were removed from the inter-
vention session in case of poor perfor-
mance of system components. This was
deﬁned by consensus of all clinical part-
ners and according to a predeﬁned and
objective set of implementation rules
(Supplementary Table 2). Linear interpo-
lation was used between CGM data
points to allow for 1-min pairing of YSI
and CGMdata. If.3 h data weremissing,
no interpolation was performed. For each
outcome, a repeated-measures ANOVA
Figure 1dOverview of the admission day. Patients underwent OL or CL control and were served
three meals. The admission day also included an exercise bout. CL control was continuous for 23 h.
Table 1dGlucose-derived outcomes and hypoglycemic measures: percent time in target, hypoglycemia, severe hypoglycemia, and
hyperglycemia
OL iAP CAM
Overall
P
CAM
vs. OL
iAP
vs. OL
ITT
Percent time in target 62.6 (15.8) 59.2 (16.3) 58.3 (17.6) 0.377 NA NA
Mean glucose (mmol/L) 7.19 (1.40) 8.15 (1.27) 8.26 (1.38) 0.001 0.001 0.001
Percent hypoglycemia ,3.9 mmol/L 6.37 (15.49) 2.10 (5.14) 2.03 (5.78) 0.001 0.001 0.001
Percent severe hypoglycemia #2.8 mmol/L 0.00 (1.16) 0.00 (0.22) 0.00 (0.00) 0.038 0.006 0.054
Percent hyperglycemia 26.7 (18.7) 36.8 (16.5) 37.9 (18.4) 0.001 0.001 0.002
PP
Percent time in target 62.8 (15.8) 59.3 (16.1) 59.6 (18.4) 0.519 NA NA
Mean glucose (mmol/L) 7.19 (1.40) 8.27 (1.14) 8.15 (1.31) 0.001 0.001 0.001
Percent hypoglycemia ,3.9 mmol/L 6.3 (16.0) 0.85 (4.13) 0.20 (5.55) 0.001 0.001 0.001
Percent severe hypoglycemia #2.8 mmol/L 0.00 (1.13) 0.00 (0.00) 0.00 (0.00) 0.017 0.020 0.005
Percent hyperglycemia 26.5 (18.7) 38.3 (16.6) 37.0 (19.7) 0.001 0.001 0.001
Data are means (SD) for glucose-derived outcomes and median (IQR) for hypoglycemia measures.
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taking into account the sequence of
study interventions was ﬁtted. When the
repeated-measures model detected a sig-
niﬁcant difference, pairwise testing was
done between all three treatments
using a two-tailed t test. In addition, dif-
ferences in outcome measures were as-
sessed between centers using manual
control and centers using fully auto-
mated control and between centers us-
ing YSI values for sensor calibrations and
those who used ﬁnger-stick values for
sensor calibration. All statistical analyses
were performed with PASW Statistics
18.0 (IBM, Armonk, NY).
RESULTS
Available data
Forty-seven patients completed the study,
and one patient dropped out after visit 1.
The PP analysis excluded on average 10.2%
of all available data (0.4% for OL, 13% for
iAP, and 17% for CAM), including time
frames with technical errors that could
affect CL control or, less frequently, human
factors such as operator error, which could
inﬂuence OL control.
Baseline characteristics
Fourteen (30%) participants were female.
Patients had a median age of 41.5 years
(interquartile range [IQR] 17.0), HbA1c
level of 7.6% (1.2), BMI of 25.0 kg/m2
(4.9), duration of diabetes of 19.8 years
(19.2), and duration of pump use of 3.6
years (6.1).
Glucose-derived outcomes: intention-
to-treat analysis
Time in target. Time in target, deﬁned
as a plasma glucose level between 3.9 and
8.0 mmol/L or up to 10 mmol/L post-
prandially, was not signiﬁcantly different
between interventions: 62.6% for OL,
59.2% for iAP, and 58.3% for CAM
(overall P = 0.377).
Time in hypoglycemia (<3.9 mmol/L).
There was signiﬁcantly less time spent in
hypoglycemia, deﬁned as a plasma glu-
cose level ,3.9 mmol/L, during CL:
6.4%, 2.1%, and 2.0% for OL, iAP, and
CAM, respectively (P = 0.001).
Time in hypoglycemia (£2.8 mmol/L).
There was signiﬁcantly less hypoglycemia
#2.8 mmol/L during CL: 0%, 0%, and
0% (P = 0.038).
Mean glucose level. Average glucose
levels were lower in OL than with CL:
7.19, 8.15, and 8.26 mmol/L (overall P =
0.001). Figure 2 depicts glucose levels
over the time course of the experiments.
Time in hyperglycemia. Time in hyper-
glycemia deﬁned as a blood glucose level
.8.0 mmol/L or .10 mmol/L postpran-
dially was lower in OL than with CL:
26.7%, 36.8%, and 37.9% (P = 0.001).
Glycemic variability. Glycemic variabil-
ity as expressed by mean absolute glucose
(MAG) and SD of blood glucose levels was
not signiﬁcantly different: MAG of 1.802
mmol/L/h (0.445) for OL, 1.969 mmol/L/h
(0.422) for iAP, and 1.833 mmol/L/h
(0.431) for CAM (overall P = 0.080). The
SD was 2.568 (0.821) for OL, 2.514
(0.767) for iAP, and 2.592 (0.799) for
CAM (overall P = 0.872).
Inter-CL algorithm differences. There
were no signiﬁcant differences in any of
these outcomes in a head-to-head com-
parison of the two CL algorithms (data
not shown) (Table 1).
Glucose-derived outcomes: per
protocol analysis
Time in target. Time in target, deﬁned as a
blood glucose level between 3.9 and 8.0
mmol/L or up to 10mmol/L postprandially,
was not different between interventions:
62.8%, 59.3%, and 59.6% (P = 0.519).
Time in hypoglycemia (<3.9 mmol/L).
There was signiﬁcantly less time spent in
hypoglycemia, deﬁned as a blood glucose
level ,3.9 mmol/L, during CL: 6.3%,
0.85, and 0.2% (P = 0.001).
Time in hypoglycemia (£2.8 mmol/L).
There was signiﬁcantly less hypoglycemia
(#2.8 mmol/L) with CL: 0%, 0%, and 0%
(P = 0.017).
Mean glucose level. Mean glucose level
was signiﬁcantly lower in OL than with
CL: 7.19, 8.27, and 8.15 mmol/L (P =
0.001).
Time in hyperglycemia. Time in hyper-
glycemia deﬁned as a blood glucose level
.8.0 mmol/L or .10 mmol/L postpran-
dially was lower in OL than with CL:
26.5%, 38.3%, and 37.0% (P = 0.001).
Glycemic variability. Glycemic variabil-
ity as expressed by MAG (SD) of blood
glucose levels was not signiﬁcantly differ-
ent: MAG of 1.798 mmol/L/h (0.438) for
OL, 1.982 mmol/L/h (0.505) for iAP, and
1.816mmol/L/h (0.484) for CAM (overall
P = 0.051). The SD was 2.569 mmol/L/h
(0.821) for OL, 2.337 mmol/L/h (0.766)
for iAP, and 2.392 mmol/L/h (0.681) for
CAM (overall P = 0.257).
Interalgorithm differences. There were
no signiﬁcant differences in any of these
outcomes between the two CL algorithms
(Table 1).
Additional analyses
CGM performance. The mean absolute
relative difference of the CGM data com-
pared with reference values was 15.1%
(9.2) in the ITT analysis versus 14.1%
(6.0) in the PP analysis. Mean absolute
relative difference was calculated per sub-
ject and then averaged.
Manual versus automated centers. There
were no differences in outcome measures
between centers that used manual control
versus those who used fully automated
control (data not shown, ITT analysis),
Figure 2dMean glucose proﬁles over time for OL, CAM, and iAP. Meals were given at 1900 h,
0800 h, and 1200 h. Exercise was performed at 1500 h. The dashed lines mark the target range.
m, minute.
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except in the case of time in target for the
CAM algorithm, which showed a higher
time in target in the manual centers (64.7%
[14.4] versus 51.7% [18.4] in automated
centers P = 0.010), and for time spent in
hyperglycemia, which was lower in manual
centers (31.6% [15.0] versus 44.4% [19.6]
in automated centers, P = 0.016).
Blood glucose meter versus YSI cali-
bration. There were no differences in any
of the glucose outcomemeasures between
those centers calibrating the CGM devices
with YSI values and those calibrating with
blood glucose meter measurements (data
not shown, ITT analysis).
Insulin parameters. The total number of
infused insulin units per hour (ITT anal-
ysis) was lower in CL than with OL:
median 1.80 IU/h (interquartile range
[IQR] 1.0), 1.70 IU/h (0.70), and 1.60
IU/h (0.60) for OL, iAP, and CAM, re-
spectively (P = 0.001). The difference be-
tween CL algorithms, with CAM infusing
less than with iAP, was also signiﬁcant
(P = 0.001). Subsequently, the mean
plasma insulin concentrations were
higher in OL than with CL: 160.2 pmol/L
(109.7), 156.2 pmol/L (114.2), and 138.7
pmol/L (107.0) (P = 0.001). This difference
was also signiﬁcant between iAP and CAM
algorithms (P = 0.009). Mean postprandial
insulin infusion proﬁles per algorithm are
depicted in Supplementary Fig. 1.
Safety parameters. The manual override
function of the system was never used in
any of the experiments.
Rescue carbohydrates. The number of
events in which a carbohydrate snack was
given to the patient as a safety precaution
when the patient was in hypoglycemia
was signiﬁcantly lower in CL (ITT analy-
sis). This occurred a median of 0 (IQR
1.0) times per patient for CAM, 0 (1.0)
times for iAP, and 1.0 (2.0) times for OL
(total number of events 20, 30, and 78 for
CAM, iAP, and OL, respectively; overall
P = 0.001) with no statistical difference
between the CL algorithms P = 0.598).
In the PP Analysis, there was a median
of 0 (0.0) times per patient for CAM,
0 (0.0) times for iAP, and 1.0 (2.0) times
for OL (total number of events 11, 10, and
76 forCAM, iAP, andOL, respectively; over-
all P = 0.001; with no statistical difference
between the CL algorithms, P = 0.861).
CONCLUSIONSdIn the largest mul-
ticenter CL trial performed so far with
overnight and daytime control, which
incorporated bothmeal and exercise chal-
lenges, we showed that either two CL
systems can keep glucose in the target
range comparable with patient’s self-
management of CSII, with the beneﬁt of
signiﬁcantly less time spent in hypogly-
cemia. Reduction of time spent in hypo-
glycemia is important in view of future
home use of such algorithm-driven insulin-
infusion systems.
This, however, came at the expense of
higher mean glucose values and more
time spent in hyperglycemia. We think
that the latter was due to intentional
detuning of both algorithms before com-
mencement of this trial, with respect to
previous studies (15,18), to enhance
safety. Lower insulin levels during CL in
both algorithms support this hypothesis,
especially in the CAM algorithm, where
earlier overnight experiments showed
similar mean insulin and similar mean
glucose levels during OL and CL control
(15). Similarly, in previous 18-h experi-
ments the iAP algorithm reduced mean
glucose (18). Detuning was primarily
done to negate challenges with accuracy
and functionality of the Dexcom Seven
plus sensor. Because of the possibility of
occasional but substantial overread, de-
tuning of algorithms was necessary. Sec-
ond, the algorithms had not been
designed to accommodate an exercise
bout. Now that the trial is completed
and the next generation of CGM has be-
come available, there is room for retuning
the algorithms to enhance efﬁcacy. In ad-
dition to detuning, there is of course a
well-known inverse relation between
mean glucose achieved and hypoglycemia
in T1DM (21). This trial was conducted in
patients with fairly good glycemic control
(median HbA1c 7.6%), and although
mean glucose in CL was higher than in
OL, time in target range during CL was
acceptable.
Another limitation was in the assess-
ment of the postexercise period, which
was relatively short; there are no data
available regarding the occurrence of
hypoglycemia beyond 3 h postexercise.
Also, this study was limited in that in
three centers, fully automated control was
not allowed for regulatory reasons. Be-
cause all required manual actions could
not be completed within 5 min, the
control cycle in manual centers was
once every 15 min. However, this only
affected the iAP algorithm, as the CAM
algorithm had a 15-min control cycle
both in automated and manual control
centers. In this study, manual mealtime
announcements were used, which has as
an important advantage: more rapid rises
in insulinemia appear than with a fully CL
approach. However, mealtime announce-
ment including its content is severely
dependent on carbohydrate counting by
patients, which could limit its usefulness
in real-life settings.
This trial also showed that CL experi-
ments can be performed in relatively
inexperienced centers, extending the ex-
ternal validity of the results beyond the
centers that have been doing such experi-
ments for years and where close collabo-
ration between algorithm developers and
clinical researchers is present.
For moving forward in terms of min-
iaturization of the system, many of the
supporting software layers will be re-
moved and software will be embedded,
which most likely will decrease the
amount of software failures signiﬁcantly.
With the results of the current trial and
further miniaturization, we feel experi-
ments outside the clinical research center
are now needed tomove the ﬁeld forward.
In particular, trials with an extended
period of CL control are needed to assess
long-term effects on HbA1c levels.
In conclusion, we show that a full day
of CL glucose control is possible, even
when systems are challenged with meals
and exercise, and that the level of glyce-
mic control is comparable with OL con-
trol. CL control resulted in less time spent
in hypoglycemia at the expense of higher
mean glucose with intentionally detuned
algorithms according to the “safety ﬁrst”
principle. CL control may be achieved
with currently available insulin pumps
and sensors, and AP experiments can be
brought into the homes of patients with
T1DM.
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